Certara, Inc. CERT 深 沪
已收盘 05-15 16:00:00 美东时间
4.48
-0.130
-2.82%
华盛通- 最 高4.73
- 今 开4.61
- 成交量 304.28万股
- 最 低 4.45
- 昨 收 4.61
- 总市值 6.87亿
- 52周最高 13.88
- 市盈率 静 --
- 换手率 1.98%
- 52周最低 4.45
- 委 比 -78.51%
- 总股本 1.53亿
- 历史最高 45.48
- 量 比 0.52
- 振 幅 6.07%
- 历史最低 4.45
- 每 手 1
- 风险率 2.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
Baird Maintains Neutral on Certara, Lowers Price Target to $6
Baird analyst Joe Vruwink maintains Certara (NASDAQ:CERT) with a Neutral and lowers the price target from $7 to $6.
05-12 19:39
Certara expects $395M-$405M 2026 revenue following medical writing divestiture
Earnings Call Insights: Certara (CERT) Q1 2026 Management View “First quarter performance was in line with our expectations, but does not reflect the company's potential,” said CEO Jon Resnick, adding...
05-12 01:01
S&P 500 Tops 7,400 As Copper Hits Record Highs: Stock Market Today
Small caps lead a mixed Wall Street session as Trump rejects Iran's peace response, sending crude back above $97, copper to a record and silver up 7%.
05-12 00:51
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Certara Divests Medical Writing Unit to Refocus Strategy
Certara ( ($CERT) ) has shared an update. Certara reported first‑quarter 2026 r...
05-11 18:57
Certara Q1 revenue slightly beats estimates on software demand
Certara Q1 revenue slightly beats estimates on software demand Overview Biosimulation software provider's Q1 revenue rose 1%, slightly beating analyst expectations Adjusted EPS for Q1 missed analyst expectations Company completed sale of medical writing and regulatory services business in Q1 Outlook
05-11 18:34
Certara Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $106.900M Beat $106.095M Estimate
Certara (NASDAQ:CERT) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 35.71 percent decrease over earnings of $0.14 per share from the same
05-11 18:25
Altasciences And Certara Announce Strategic Partnership To Accelerate Early-Phase Development Programs
Altasciences, a fully integrated drug development solution company, andCertara (NASDAQ:CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase
05-07 20:09
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst
Certara stock rises after $135 million divestiture to Veristat as analysts weigh MIDD focus and improving biopharma demand.
04-23 03:23
